Trial Profile
A study to evaluate the relation between the efficacy and early Immune Related Advers Events of Nivolmab in patients with non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 31 May 2016 New trial record